Bottom line
ASTLX vs CAIBX: the short answer
ASTLX (Astor Dynamic Allocation Fund) and CAIBX (Capital Income Builder) are both mutual funds.
CAIBX is cheaper at 0.58% vs 1.74% — a difference of $116 a year per $10,000 invested.
Over five years, CAIBX returned +4.5% a year vs +3.4% for ASTLX.
Updated Nov 19, 2026
ASTLX vs CAIBX side by side
| ASTLX | CAIBX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Fidelity | American Funds (Capital Group) |
| Category | Allocation / Balanced | Allocation / Balanced |
| Expense ratio | 1.74% | 0.58% |
| Annual cost per $10k | $174 | $58 |
| 10-yr cost on $10k (prospectus) | $2,813 | $1,259 |
| Max front load | 4.75% | 5.75% |
| 12b-1 fee | 0.25% | 0.25% |
| 1-yr return | +5.2% | +3.9% |
| 5-yr return (annualized) | +3.4% | +4.5% |
| 10-yr return (annualized) | +4.6% | +4.9% |
| Best quarter | +11.2% | +11.4% |
| Worst quarter | −13.2% | −15.4% |
| Net assets (fund) | — | $130.5B |
| Number of holdings | — | 2,791 |
| Portfolio turnover | 142% | 5% |
| Returns as of | Dec 31, 2024 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
ASTLX and CAIBX share none of their top holdings.
ASTLX top 10
CAIBX top 10
- Capital Group Central Cash Fund — 4.22%
- Broadcom Inc — 4.02%
- Taiwan Semiconductor Manufacturing Co Ltd — 3.38%
- Philip Morris International Inc — 2.94%
- Capital Group Central Corporate Bond Fund — 2.04%
- Abbvie Inc — 1.93%
- British American Tobacco Plc — 1.85%
- Rtx Corp — 1.57%
- Jpmorgan Chase & Co — 1.17%
- Astrazeneca Plc — 1.10%
FAQ
What is the difference between ASTLX and CAIBX?
ASTLX (Astor Dynamic Allocation Fund) and CAIBX (Capital Income Builder) are both mutual funds. CAIBX is cheaper at 0.58% vs 1.74% — a difference of $116 a year per $10,000 invested.
Which is cheaper, ASTLX or CAIBX?
CAIBX has the lower expense ratio (0.58%).
Should I own both ASTLX and CAIBX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.